Summary Matrix metalloproteinases (MMPs) are zinc dependent endopeptidases implicated in cancer invasion and metastasis. Gelatin zymography was performed on 84 human breast carcinomas and seven normal breast tissues. The precursor form of MMP-2 (72 kDa) was found in 11 (12%) samples, while its two activated forms, i.e. 62 kDa and 59 kDa, were found in three (6%) and 34 (40%) samples respectively. In contrast to MMP-2, most of the samples (52%) contained MMP-9 in its precursor form. Using ELISA, MMP-1 levels were found in 12% of the samples while MMP-3 levels were found in only 2% of the samples. Levels of MMP-2, -3 and -9 correlated inversely with numbers of nodal metastases. Neither MMP-2 nor -9 levels were significantly related to patient outcome. However, patients with high levels of a 50-kDa gelatinase band after zymography had a significantly better survival than patients with low levels. This species was never observed in normal breast tissue.
The escape of breast cancer cells into neighbouring tissues can lead to the formation of distant metastasis, the most insidious aspect of cancer. It is generally believed that one key element of this metastatic process is the enhanced proteolysis of both basement membrane and stromal extracellular matrix (ECM) . Among the proteinases capable of degrading these barriers are the matrix metalloproteinases (MMPs), a family of highly homologous zincdependent endopeptidases (Matrisian, 1990) .
Based on the protein domain structure, the MMPs can be divided into five main groups (MacDougall and Matrisian, 1995) . MMP-7 or matrilysin contains the minimal number of domains, i.e., a predomain, a prodomain and a catalytic domain. MMP-3 (stromelysin-1), MMP-10 (stromelysin-2), MMP-1 1 (stromelysin-3) and MMP-12 (metalloelastase) contain an additional carboxyterminal haemopexin-like domain and represent the second group. The stromelysins have a broad substrate specificity and are capable of degrading many extracellular components, e.g. laminin, fibronectin and proteoglycans. The third group is composed of MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase) and MMP-13 (collagenase 3). These MMPs degrade fibrillar collagens and all members of this group have a distinct size and sequence composition in their hinge domain. The most recently described group of MMPs are the membrane-type matrix metalloproteinases. At least some members of this group play a role in the activation of MMP-2 (Sato et al, 1994; Takino et al, 1995) . MMP-2 (gelatinase A) and MMP-9 (gelatinase B) account for a separate class based on the presence of a fibronectin-like domain.
Gelatinases are able to cleave both the denatured forms of collagen and type IV collagen found in basement membranes. In addition to the fibronectin-like domain, MMP-2 and -9 contain a gelatinbinding domain that endows them with high affinity for gelatin. This property is used in the concentration or in the purification of these enzymes by affinity chromatography on gelatin-Sepharose beads (Chen et al, 1991; Remacle et al, 1995) .
The MMPs are all produced as latent proenzymes which undergo proteolytic cleavage of an amino terminal domain during activation (Atkinson et al, 1992; Kleiner and Stetler-Stevenson, 1993) . The net activity of MMPs is determined by the amount of proenzyme expressed, the extent to which the proenzyme is activated and the local concentration of specific tissue inhibitors of MMPs, i.e. the TIMPs. Four different TIMPS have been identified: TIMP-1, TIMP-2, TIMP-3 and TIMP-4 (DeClerck et al, 1989; Leco et al, 1994; Apte et al, 1995; Green et al, 1996) . TIMP-1 and TIMP-2 have molecular weights of 28.5 and 21 kDa respectively, and appear to act by forming 1:1 stoichiometric complexes with the active MMP. However, TIMP-1 also binds to the precursor form of MMP-9, while TIMP-2 binds to the precursor form of MMP-2 (Wilhelm et al, 1989) , suggesting that they may selectively modulate activity of these enzymes (Fridman et al, 1992) . Considerable evidence from model systems suggests that certain MMPs play a role in cancer invasion and metastasis (Alvarez et al, 1990; Hoyhtya et al, 1990; DeClerck et al, 1992; Duffy, 1992; Aznavooran et al, 1993) . Consistent with their role in experimental metastasis, gelatinases, in particular, have been found to be elevated in many human cancers such as breast (Monteagudo et al, 1990 ; Davies et al, 1993) , colon (D'Errico et al, 1991) , prostate (Stearns and Wang, 1993) and ovarian (Autio-Harmainen et al, 1993) . Tumour cells may either secrete these enzymes themselves or induce the host cells within the tumour stroma to produce them (Noel et al, 1994; Ito et al, 1995) .
The aim of this investigation was to measure different MMPs in extracts of both normal breast tissue and primary breast cancers. In the breast cancers, we related levels of the different MMPs to pathological characteristics of the tumour and to patient outcome. Gelatin zymography was used to resolve the activated species from the stored at -75°C until assayed. Protein concentrations of the extracts were determined using the Bio-Rad protein assay. The oestrogen receptor (ER) and progesterone receptor (PR) content of the primary breast tumours were measured using ELISA as previously described by Duffy et al (1986) . Details of the axillary node status, tumour size, ER and PR levels of the 84 patients on whom the MMP assays were prepared are summarized in Table 1 . Of these 84 patients, follow-up data were available on 80. Median patient follow-up was 25 months.
Gelatin zymography
Gelatin zymography was performed as previously described (Heussen and Dowdle, 1980; Remacle et al, 1995 Medium conditioned by subconfluent human fibrosarcoma HT1080 cells treated with 12-O-tetradecanoylphorbol-13-acetate (TPA) (10 ng ml-') for 48 h, was used as gelatinase standards as previously described (Brown et al, 1993; Davies et al, 1993; Liabakk et al, 1996) . The identities of the gelatinase species in this medium have been previously determined by Western blot analysis (Brown et al, 1990 (Brown et al, , 1993 Mr 92 000-9 Mr 72 _, ...
Mr59 000
Mr 50 000 (1998) 77(6), [926] [927] [928] [929] [930] [931] . (Takaoda, Toyama 933, Japan) . According to the supplier, the MMP-l assay primarily detects the proform. However, it also detects the active form, MMP-I/TIMP-1 complex and MMP-1/TIMP-2 complex with an efficiency of approximately 50%, 10% and less than 3% respectively. The MMP-3 ELISA also detects the pro-and active forms as well as MMP-3/TIMP complexes. However, the relative efficiency in detecting these different forms of MMP-3 was not stated in the kit insert. An arbitrary cut-off point of 1 ng mg-' protein and 5 ng mg-' protein was used for MMP-1 and MMP-3 respectively.
For standardization, we used purified precursor forms of human MMP-1 and MMP-3 provided in the ELISA kits.
Statistical analysis
Levels of the different MMPs were related to both one another and to established prognostic markers for breast cancer using the Spearman-coefficient of rank correlation. Differences in patient outcome between groups were determined using the log-rank test.
RESULTS

MMPs with gelatinolytic activities in normal breast samples
We have performed gelatin zymography on normal breast tissue. The gelatinolytic pattern of the seven samples analysed was constant and displayed seven different bands of 116, 92, 84, 77, 72, 62 and 45 kDa (Figure IA) . A 150-kDa species was detected in only one sample. Gelatinase A was detected in its proform (72 kDa) and intermediate active form (62 kDa). However, its fully active 59-kDa form was never observed.
Levels of the different MMPs in breast cancers
The proportion of breast cancers positive for the different MMPs is shown in Table 2 . After gelatin zymography a total of 11 different bands were seen with molecular weights ranging from 36.5 to 150 kDa. However, as shown in Figure iB , both the number and intensity of bands varied from sample to sample. Inhibition with 20 mi EDTA ( Figure IC ) or with 1 mi phenanthroline (data not shown) indicated the metalloproteinase nature of these gelatinase bands.
Three different forms of gelatinase A (MMP-2) were detected, i.e. the 72-kDa progelatinase A and its two activated forms, migrating as 62-and 59-kDa proteins. While the precursor form was found in only 12% of samples, the 62-kDa band was found in 6% and the 59-kDa band in 40%. The 59-kDa activated form of gelatinase A was observed in 10 of 11 (91%) tumours positive for the 72-kDa species, and in 24 of 73 (33%) samples lacking this band (P = 0.0022). Furthermore, as shown in Table 2 , the mean activity of the 59-kDa activated form was approximatively twice as high as that of the progelatinase 72-kDa form. These results demonstrate that in most of the tumour samples gelatinase A is detected in its 59-kDa activated form.
The precursor form of gelatinase B (92-kDa band) was found in 52% of the samples, while its activated form (84-kDa band) was present in only 10%. The 84-kDa activated form of gelatinase B was detected in S out of 44 (11%) tumour samples containing the 92-kDa proenzyme and in 3 of 40 (7%) samples without this species (P = not Time (years) Figure 3 Relationship between the 50-kDa gelatinase activity levels and overall survival in patients with breast cancer. The cut-off point used was detectable levels of the 50-kDa band. Median follow-up was 25 months (P = 0.001 4, log rank chi-square 10.2) significant). These results suggest that gelatinase B was mainly expressed as its 92-kDa zymogen form. Furthermore, the mean activity of the 84-kDa activated gelatinase B form detected in some primary tumours was about five times lower than that of the progelatinase B (Table 2 ). The proportion of samples positive for the other gelatinases is summarized in Table 2 . It is interesting to note that the 50-kDa species observed in 52% of tumour extracts was never observed in normal breast tissue ( Figure 1A) .
MMP-1 immunoreactivity levels (greater than 1 ng mg-' protein) were found in 12% of samples while MMP-3 immunoreactivity (greater than 5 ng mg-' protein) was detected in only 2%. Mean levels of MMP-l were 0.283 ng mg-1 protein (range 0-4.30 ng mg-' protein), while mean levels of MMP-3 were 0.338 ng mg-' protein (range 0-7.50 ng mg-' protein).
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Relationship between the different MMPs 
Relationship between different MMPs and clinicopathological parameters
None of the well-characterized metalloproteinases, such as MMP-1, -3, gelatinase A or B, correlated significantly with tumour size. However, levels of the 50-kDa band showed a weak, but statistically significant, inverse relationship with size (r = -0.245, P = 0.0442). The nature of this 50-kDa band has not yet been identified. In an attempt to characterize this species, different cancer extracts containing this 50-kDa form were pooled and incubated with gelatin-Sepharose beads before analysis by gelatin zymography. The 50-kDa gelatinolytic band was recovered in the unbound fraction (Figure 2 ). These results indicated that the 50-kDa species did not contain the gelatin-binding domain characteristic of gelatinases A and B and furthermore that it could not be a degradation product of these enzymes.
In contrast to the lack of correlation with tumour size, certain MMPs correlated inversely with nodal status (Table 4 ). There was no significant relationship between high levels of MMP-2 or -9 and patient outcome. Because of the low proportion of tumours positive for both MMP-1 (12%) and MMP-3 (2%), it was not possible to reliably relate levels of these MMPs to patient outcome. However, as shown in Figure 3 , patients with a high level of the 50-kDa species had a significantly better survival than patients with low levels of this form (P = 0.0014). The relationship between the 50-kDa band and disease-free interval was not significant.
DISCUSSION
This study describes the distribution of multiple MMPs in normal and malignant breast tissues. Using ELISA, we show that MMP-1 and MMP-3 are detectable in only a minority of breast cancers. To our knowledge, neither MMP-1 nor -3 protein levels have previously been assayed by a quantitative assay in breast cancer. Using in situ hybridization, Polette et al (1993) found expression of both MMP-l and -3 in 2 out of 17 breast carcinomas, while Heppner et al (1996) found expression of both proteinases in 3 out of 1 1 invasive breast cancers. Our results using ELISA are thus in agreement with the finding using in situ hybridization, with both approaches suggesting that both MMP-1 and -3 are only expressed by a small proportion of human breast cancers.
Using gelatin zymography we found 11 different bands in tumour extracts. MMP-9 (gelatinase B) was mainly detected as a zymogen (92 kDa) and not as an active enzyme (84 kDa). On the contrary, gelatinolytic activity corresponding to one of the two activated forms of MMP-2 (i.e., the 59-kDa form) were more frequently observed than the precursor form and were more intense than that corresponding to progelatinase A (72 kDa). On the contrary, this fully active form of gelatinase A was never observed in the normal breast samples analysed. Our findings are in agreement with other studies suggesting that the activation of MMP-2 (gelatinase A) is a more common event in human breast British Journal of Cancer (1998) carcinoma than the activation of MMP-9 (gelatinase B) (Brown et al, 1993; Davies et al, 1993) . The proportion of samples containing progelatinase B in the present investigation, i.e. 52%, was very similar to that previously described (Brown et al, 1993; Davies et al, 1993) . However, in contrast to previous reports (Brown et al, 1993; Davies et al, 1993; Sik Lee et al, 1996) , we found progelatinase A in only a minority of samples. In the present study, as mentioned above, most of this MMP was detected in its activated 59-kDa form. These different findings on the proportion of samples positive for progelatinase A may relate to factors such as composition of homogenization buffers, handling and storage of tumours and/or cell-free extracts.
Previously, using ELISA, we showed a significant correlation between levels of MMP-8 and -9 in breast cancer (Duffy et al, 1995) . In the present investigation, we show a significant association between MMP-9 activity and MMP-2 activity (both precursor and active forms). However, MMP-9 activity showed no significant relation with either levels of MMP-1 or MMP-3. These findings suggest that similar factors may be controlling the levels of different MMPs in breast cancer. In this investigation, no significant association was found between levels of the established MMPs and tumour size. Using a smaller number of samples (i.e. 20), Brown et al (1993) also found no relationship between activity levels of either MMP-2 or -9 and tumour size. However, in contrast to Brown et al (1993) , we found a weak but significant inverse relationship between axillary node metastases and levels of MMP-2,-3 and-9.
Previously, high levels of a number of different proteases implicated in metastasis, such as urokinase plasminogen activator, cathepsin B and cathepsin D have been found to predict poor prognosis in patients with breast cancer (for review, see Duffy, 1992) . In this preliminary study of 84 patients with a median follow-up time of 25 months, no significant relationship was found between levels of either MMP-1, -2, -3 or -9 and patient outcome. Similarly, using immunohistochemistry, Visscher et al (1994) found no relationship between levels of either MMP-2 or MMP-9 and prognosis in breast cancer, while Daidone et al (1991) found no association between 'collagenase IV' levels and either relapse-free survival or overall survival in axillary node-negative breast cancer patients. Unlike the MMPs investigated in the present study, we have recently shown that levels of at least one MMP, i.e. stromelysin-3, correlates with outcome in breast cancer patients (Chenard et al, 1996) . It is also worth noting that while MMP-2 and -9 do not appear to be associated with prognosis in breast cancer, they are predictive of outcome on at least one type of cancer, i.e. gastric carcinoma (Sier et al, 1996) . More sensitive assays are required to address the relationship between levels of both MMP-1 and -3, and tumour aggressiveness.
While levels of MMP-1, -2, -3 and -9 were not related to patient outcome in the present study, high levels of a previously unreported gelatinase, i.e. a 50-kDa band, were associated with improved overall survival. This 50-kDa species was never observed in normal breast extracts analysed. Although the identity of the 50-kDa band is unknown, our data suggests that it is unrelated to interstitial collagenase or to stromelysin-1, which exhibit similar molecular weight, but which display only weak gelatinase activity (Brown et al, 1990) . Furthermore, the lack of binding of this 50-kDa form to gelatin-Sepharose beads suggests that this enzymatic species could not be a degradation product of the known gelatinases. Indeed, gelatinase A and B are both characterized by a gelatin binding site in their catalytic domain (Matrisian, 1990; Kleiner and Stetler-Stevenson, 1993) . This domain to be appears to be implicated in the gelatinolytic activity, as a mutant of gelatinase A from which this domain has been deleted retained only 10% of its activity against gelatin (Murphy et al, 1994) .
The lack of correlation between levels of MMP-2 and -9 and patient prognosis observed in this study does not necessarily mean that these proteinases are not involved in the metastasis of breast cancer. It should be borne in mind that this is a preliminary study with only 80 patients having follow-up and the median follow-up being only 25 months. Furthermore, no attempt was made in the present study to establish the optimum conditions for extracting the different MMPs. Finally, the ratio of MMPs to TIMPs may be more important in determining clinical outcome than levels of MMPs alone. Further studies are thus clearly necessary to establish whether MMP-1, -2, -3 or -9 are related to patient prognosis.
Irrespective of whether or not the above MMPs are related to clinical outcome, their measurement in primary cancers might be useful in predicting responses to MMP inhibitors. Inhibitors of MMPs have been shown to prevent or decrease the formation of metastases in animal model systems (Brown and Giavazzi, 1995) . Furthermore, in recent years, certain MMP inhibitors have entered clinical trials. A goal to the future should be to see whether any relationship exists between the levels and the profile of MMPs in a cancer and response to this new form of cancer therapy.
